Literature DB >> 16788134

Clinical trial investigators and their prescribing patterns: another dimension to the relationship between physician investigators and the pharmaceutical industry.

Bruce M Psaty, Drummond Rennie.   

Abstract

Mesh：

Year:  2006        PMID： 16788134     DOI： 10.1001/jama.295.23.2787

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Research ethics. Rethinking research ethics: the case of postmarketing trials.

Authors:  Alex John London; Jonathan Kimmelman; Benjamin Carlisle
Journal:  Science       Date:  2012-05-04       Impact factor: 47.728

2.  Does family medicine have a professional obligation to play a leading role in pharmaceutical industry-sponsored drug research?: no.

Authors:  Joel Lexchin
Journal:  Can Fam Physician       Date:  2011-08       Impact factor: 3.275

3.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

Review 4.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

5.  Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications.

Authors:  Joel Lexchin
Journal:  Sci Eng Ethics       Date:  2011-02-15       Impact factor: 3.525

6.  Study of the strength of the evidence and the redundancy of the research on pharmacological treatment for Alzheimer's disease: a cumulative meta-analysis and trial sequential analysis.

Authors:  Lídia Blanco-Silvente; Xavier Castells; Josep Garre-Olmo; Joan Vilalta-Franch; Marc Saez; Maria Antònia Barceló; Dolors Capellà
Journal:  Eur J Clin Pharmacol       Date:  2019-08-21       Impact factor: 2.953

7.  Promoting transparency in pharmaceutical industry-sponsored research.

Authors:  Joseph S Ross; Cary P Gross; Harlan M Krumholz
Journal:  Am J Public Health       Date:  2011-11-28       Impact factor: 9.308

8.  Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.

Authors:  Ali T Taher; John B Porter; Antonis Kattamis; Vip Viprakasit; M Domenica Cappellini
Journal:  Drug Des Devel Ther       Date:  2016-12-15       Impact factor: 4.162

9.  Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.

Authors:  Angela Spelsberg; Christof Prugger; Peter Doshi; Kerstin Ostrowski; Thomas Witte; Dieter Hüsgen; Ulrich Keil
Journal:  BMJ       Date:  2017-02-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.